Jazz Pharmaceuticals v. Granules India: Consent Judgment Blocks Xywav® Generic
Jazz Pharmaceuticals Ireland Limited filed suit in the District of New Jersey against Granules India Limited, asserting 14 patents covering its Xywav® calcium, magnesium, potassium, and sodium oxybates oral solution. The case resolved in 225 days with a court-entered consent judgment permanently enjoining Granules from commercialising its ANDA No. 220725 product until all 14 patents-in-suit expire.
14-Patent Xywav® Wall Holds: How Jazz Locked Out Granules India
On 13 August 2025, Jazz Pharmaceuticals Ireland Limited filed suit against Granules India Limited in the U.S. District Court for the District of New Jersey, asserting infringement of 14 U.S. patents covering its Xywav® product — a calcium, magnesium, potassium, and sodium oxybates oral solution (NDA 212690) used in the treatment of cataplexy and excessive daytime sleepiness. The triggering event was Granules' filing of Abbreviated New Drug Application No. 220725, which referenced Jazz's NDA and included Paragraph IV certifications challenging the patents-in-suit.
The case resolved on 26 March 2026 via a consent judgment stipulated by both parties and entered by the court. The judgment permanently enjoins Granules and its successors and assigns from making, using, selling, offering to sell, importing, or distributing the Granules ANDA Product in the United States until expiration of all 14 patents-in-suit. The court retained jurisdiction to enforce the consent judgment. All claims, counterclaims, and affirmative defenses were dismissed with prejudice and without costs or attorneys' fees to any party. Notably, the judgment expressly preserves Granules' right to maintain its Paragraph IV certification and to engage in activities permitted under 35 U.S.C. § 271(e)(1), and does not restrict FDA approval of ANDA No. 220725.
Resolution in 225 days — before any claim construction or substantive merits ruling — is consistent with early-stage ANDA litigation settlements in which the ANDA filer accepts an injunction in exchange for certainty. Whether any authorised generic, launch date, or licensing arrangement underlies the agreement is not disclosed in the available public record. The preservation of the Paragraph IV certification and the explicit non-restriction on FDA approval suggest the parties contemplated a potential future commercialisation pathway, though the specific terms governing any such pathway are not in the record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 225 days
Days from filing to consent judgment — resolved in under 8 months
US8,591,922 and 13 further patents — Xywav® oxybate oral solution portfolio
Any company developing a generic or novel oxybate oral solution — particularly one referencing NDA 212690 or targeting the calcium, magnesium, potassium, and sodium oxybates therapeutic space — faces direct exposure to this 14-patent cluster. This case confirms that Jazz will assert the full portfolio in ANDA litigation. R&D teams formulating mixed-salt oxybate products, and business development teams evaluating ANDA acquisitions in the CNS sleep space, should treat a full FTO across all 14 patents as a prerequisite, not an afterthought.
Official order — verbatim text
The consent judgment is comprehensive in scope: it enjoins Granules by name and extends to its successors and assigns, covering all forms of commercialisation of ANDA No. 220725 in the United States. Critically, the order preserves Granules' Paragraph IV certification rights and 35 U.S.C. § 271(e)(1) research exemption, and expressly does not restrict FDA approval — suggesting the parties structured the judgment to allow for a potential future authorised or licensed pathway, the specific terms of which are not disclosed in the available record.
Consent judgment: what the agreed resolution means for both parties
A binding court judgment entered on agreed terms
A consent judgment is not merely a settlement agreement — it is a court-entered judgment that carries full judicial authority. Both parties stipulated to its terms; the court ordered, adjudged, and decreed it on 26 March 2026. The court expressly retained jurisdiction to enforce the judgment and resolve any disputes arising from it, giving Jazz an enforcement mechanism beyond ordinary contract remedies.
Court-entered & enforceableJazz secures injunction across all 14 patents
Jazz obtained a permanent injunction blocking Granules from commercialising ANDA No. 220725 until every one of the 14 patents-in-suit expires. Compliance obligations extend to Granules' successors and assigns, limiting the risk that a corporate restructuring could circumvent the injunction. Jazz also retains the right to enforce the judgment directly, reinforcing its exclusivity position over Xywav® in the U.S. market.
Permanent injunction securedGranules enjoined, but FDA approval path preserved
Granules is permanently enjoined from commercialising its oxybate ANDA product without Jazz's specific authorisation. However, the consent judgment expressly permits Granules to maintain its Paragraph IV certification and to engage in research and development activities under 35 U.S.C. § 271(e)(1). FDA approval of ANDA No. 220725 is not blocked. The specific terms governing any future commercialisation pathway are not disclosed in the available public record.
ANDA approval path intact14-patent wall raises the barrier for all oxybate generics
With 14 patents-in-suit upheld by consent, Jazz's Xywav® portfolio signals a formidable exclusivity position. Other ANDA filers in the oxybate space should assess the breadth of this patent cluster — spanning formulation, composition, and method claims across a range of issuance dates — before advancing their own Paragraph IV strategies. The no-costs outcome removes one deterrent to future challengers but does not diminish the injunctive precedent.
High barrier for generic entryFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Jazz Pharmaceuticals Ireland Limited | Company | /Search in Eureka ↗ |
| Defendant | GRANULES INDIA LIMITED | Individual | /Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Defendant counsel | BRADFORD C. FRESE | Attorney | Counsel for GRANULES INDIA LIMITEDSearch in Eureka ↗ |
| Defendant counsel | JANINE A. CARLAN | Attorney | Counsel for GRANULES INDIA LIMITEDSearch in Eureka ↗ |
| Defendant counsel | Katherine Ann Escanlar | Attorney | Counsel for GRANULES INDIA LIMITEDSearch in Eureka ↗ |
| Defendant counsel | Richard J. Berman | Attorney | Counsel for GRANULES INDIA LIMITEDSearch in Eureka ↗ |
| Defendant law firm | Saiber LLC | Law Firm | Representing GRANULES INDIA LIMITEDSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the oxybate and CNS sleep therapeutics IP space
Forward-looking patent intelligence signals derived from Jazz Pharmaceuticals' 14-patent Xywav® portfolio and Granules India's ANDA challenge — relevant to CNS formulation R&D and oxybate generic strategy.
Jazz's oxybate patent filings: how deep does the wall go?
Jazz has constructed a 14-patent portfolio spanning 2013–2024, suggesting active continuation filing strategy around Xywav®. Mapping the full Jazz oxybate patent family — including pending applications beyond the patents-in-suit — reveals the likely extent of exclusivity and any gaps that could support design-around or FTO strategies for CNS drug developers.
Jazz oxybate portfolio depthMixed-salt oxybate formulation: who else is filing?
The shift from sodium oxybate (Xyrem®) to mixed-salt oxybate (Xywav®) reflects a broader trend toward reduced-sodium CNS formulations. Tracking global patent filings in mixed-salt gamma-hydroxybutyrate and oxybate formulation technology can surface emerging competitors, alternative salt ratios, and novel delivery mechanisms that may fall outside Jazz's existing claim scope.
Mixed-salt oxybate filing trendsGranules India's patent and R&D position in CNS generics
Granules India is an active ANDA filer across multiple therapeutic areas. Analysing its patent filings and ANDA pipeline in the CNS and sleep disorder space provides context for how it may pursue design-around opportunities or future oxybate commercialisation once patent exclusivity periods begin to expire.
Granules India CNS pipelineAdjacent oxybate innovation: formulation and delivery white space
Jazz's 14-patent cluster focuses on specific mixed-salt compositions and dosing methods for oral solution delivery. Adjacent areas — including novel delivery mechanisms, extended-release formulations, or alternative oxybate salt combinations not covered by existing claims — may represent white-space opportunities for R&D teams seeking to enter the CNS sleep therapeutics market without triggering Jazz's portfolio.
Oxybate formulation white spaceSimilar ANDA patent infringement cases in the CNS pharmaceutical space
Explore related Hatch-Waxman ANDA infringement cases involving oxybate or CNS formulation patents litigated in the District of New Jersey.
What this case signals for the oxybate pharmaceutical IP landscape
Jazz's 14-patent consent judgment reinforces Xywav® exclusivity and raises the stakes for any generic challenger in the oxybate space.
14-patent clusters in ANDA litigation are a powerful deterrent to generic entry
Asserting 14 patents simultaneously — spanning multiple families and issuance years — significantly raises the cost and complexity for any ANDA filer. Granules accepted an injunction without a merits ruling, consistent with a challenger weighing the burden of validity and infringement litigation across 14 distinct patent claims. Generic developers targeting Xywav® should model litigation exposure across the entire portfolio, not individual patents.
Preserved Paragraph IV certification signals a potential future market entry window
The consent judgment explicitly allows Granules to maintain its Paragraph IV certification and retain FDA ANDA approval. This suggests the parties did not foreclose future commercialisation entirely. Competitors and payers monitoring the oxybate market should track patent expiration dates across all 14 patents-in-suit to identify when generic entry becomes legally available.
Jazz v GRANULES — key questions answered
The case resolved via a consent judgment entered by the U.S. District Court for the District of New Jersey on 26 March 2026. The court permanently enjoined Granules India from commercialising its ANDA No. 220725 oxybate oral solution product in the United States until expiration of all 14 patents-in-suit. All claims were dismissed with prejudice and without costs to any party.
Jazz asserted 14 U.S. patents: US8,591,922; US8,772,306; US8,901,173; US9,050,302; US9,132,107; US9,486,426; US10,195,168; US10,213,400; US10,675,258; US10,864,181; US11,253,494; US11,426,373; US11,554,102; and US11,986,446. All 14 patents are listed as Patents-in-Suit in the consent judgment and cover Jazz's Xywav® calcium, magnesium, potassium, and sodium oxybates oral solution.
Granules India is enjoined from commercialising ANDA No. 220725 in the United States without Jazz's specific authorisation until all 14 patents-in-suit expire. However, the judgment expressly does not restrict FDA approval of the ANDA, permits Granules to maintain its Paragraph IV certification, and allows activities under 35 U.S.C. § 271(e)(1). The specific terms of any future commercialisation pathway are not disclosed in the available public record.
Yes. Paragraph 10 of the consent judgment expressly states that nothing in the judgment restricts or is intended to restrict the FDA from approving ANDA No. 220725. Granules may also maintain its Paragraph IV certifications and engage in research activities permitted under 35 U.S.C. § 271(e)(1). FDA approval is decoupled from the commercial injunction.
The case resolved in 225 days — approximately 7.5 months from filing on 13 August 2025 to the consent judgment on 26 March 2026. Hatch-Waxman ANDA litigation in the District of New Jersey frequently extends to claim construction and trial over multiple years. Resolution at this early stage, before any merits briefing, is consistent with pre-trial negotiated resolutions in ANDA cases, though the specific factors driving the timeline are not disclosed in the public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.